VANCOUVER, March 03, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders and viral infections, announces it has entered into an agreement with Eurofins CDMO Alphora Inc. (“Eurofins CDMO”) for TD-0148A’s GMP…

Source

Previous articleNova Mentis Launches Autism Microbiome Study in the United States
Next articleLobe Sciences Appoints NFL Alumni Association President, Bart Oates Esq. to Advisory Board